var data={"title":"Filgrastim (including biosimilars of filgrastim): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Filgrastim (including biosimilars of filgrastim): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6197?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-patient-drug-information\" class=\"drug drug_patient\">see &quot;Filgrastim (including biosimilars of filgrastim): Patient drug information&quot;</a> and <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Filgrastim (including biosimilars of filgrastim): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171203\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Granix;</li>\n      <li>Neupogen;</li>\n      <li>Zarxio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171204\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Grastofil;</li>\n      <li>Neupogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171247\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Hematopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171207\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not administer in the period 24 hours before to 24 hours after cytotoxic chemotherapy. May round the dose to the nearest vial size for convenience and cost minimization (Ozer 2000). <b> International considerations:</b> Dosages below expressed as micrograms; 1 mcg = 100,000 units (Hoglund 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Myelosuppressive chemotherapy recipients with nonmyeloid malignancies (Neupogen [filgrastim], Zarxio [filgrastim-sndz; biosimilar], Grastofil</b> [Canadian product]<b>):</b> SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the absolute neutrophil count (ANC) reaches 10,000/mm<sup>3</sup>. Discontinue if the ANC surpasses 10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelosuppressive chemotherapy recipients with nonmyeloid malignancies (Granix [tbo-filgrastim]):</b> SubQ: 5 mcg/kg/day; continue until anticipated nadir has passed and neutrophil  count has recovered to normal range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML) following induction or consolidation chemotherapy (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the ANC reaches 10,000/mm<sup>3</sup>. Discontinue if the ANC surpasses 10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bone marrow transplantation (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> IV infusion: 10 mcg/kg/day (administer &ge;24 hours after chemotherapy and &ge;24 hours after bone marrow infusion); adjust the dose according to the duration and severity of neutropenia; recommended steps based on neutrophil response: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">When ANC &gt;1,000/mm<sup>3</sup> for 3 consecutive days: Reduce dose to 5 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If ANC remains &gt;1,000/mm<sup>3</sup> for 3 more consecutive days: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If ANC decreases to &lt;1,000/mm<sup>3</sup>: Resume at 5 mcg/kg/day. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">If ANC decreases to &lt;1,000/mm<sup>3</sup> during the 5 mcg/kg/day dose: Increase dose to 10 mcg/kg/day and follow the above steps. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hematopoietic radiation injury syndrome, acute (Neupogen):</b> SubQ: 10 mcg/kg once daily; begin as soon as possible after suspected or confirmed radiation doses &gt;2 gray (Gy) and continue filgrastim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs or ANC exceeds 10,000/mm<sup>3</sup> after the radiation-induced nadir. ASCO guidelines recommend initiating within 24 hours of exposure of a dose &ge;2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for &ge;7 days (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Peripheral blood progenitor (PBPC) cell collection and therapy (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> SubQ: 10 mcg/kg daily, usually for 6 to 7 days (with apheresis occurring on days 5, 6, and 7). Begin at least 4 days before the first apheresis and continue until the last apheresis; discontinue for WBC &gt;100,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Severe chronic neutropenia (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Congenital:</i> Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; mean dose: 6 mcg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Idiopathic:</i> Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 1.2 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cyclic:</i> Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 2.1 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Anemia in myelodysplastic syndrome (off-label use; in combination with epoetin):</b> SubQ: 300 mcg weekly in 2 to 3 divided doses (Malcovati 2013) <b>or</b> 1 mcg/kg once daily (Greenberg 2009) <b>or</b> 75 mcg, 150 mcg, or 300 mcg per dose 3 times weekly (Hellstrom-Lindberg 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hematopoietic stem cell mobilization in autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma (in combination with plerixafor; off-label combination):</b> SubQ: 10 mcg/kg once daily; begin 4 days before initiation of plerixafor; continue G-CSF on each day prior to apheresis for up to 8 days (DiPersio 2009a; DiPersio 2009b)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hepatitis C treatment-associated neutropenia (off-label use):</b> SubQ: 150 mcg once weekly to 300 mcg 3 times weekly; titrate to maintain ANC between 750 and 10,000/mm<sup>3</sup> (Younossi 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Neutropenia in advanced HIV infection (off-label use):</b> SubQ: Initial: 1 mcg/kg once daily or 300 mcg one to three times per week; titrate to maintain ANC 2,000 to 10,000/mm<sup>3</sup>; doses up to 10 mcg/kg/day or 600 mcg daily were studied (Kuritzkes 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171227\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Filgrastim (including biosimilars of filgrastim): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not administer in the period 24 hours before to 24 hours after cytotoxic chemotherapy. <b> International considerations:</b> Dosages below expressed as micrograms; 1 mcg = 100,000 units (Hoglund 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Myelosuppressive chemotherapy recipients with nonmyeloid malignancies (Neupogen [filgrastim], Zarxio [filgrastim-sndz; biosimilar], Gastrofil</b> [Canadian product]<b>):</b> SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the absolute neutrophil count (ANC) reaches 10,000/mm<sup>3</sup>. Discontinue if the ANC surpasses 10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone marrow transplantation (Neupogen, Zarxio):</b> IV infusion: 10 mcg/kg/day (administer &ge;24 hours after chemotherapy and &ge;24 hours after bone marrow infusion); adjust the dose according to the duration and severity of neutropenia; recommended steps based on neutrophil response: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When ANC &gt;1,000/mm<sup>3</sup> for 3 consecutive days: Reduce dose to 5 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ANC remains &gt;1,000/mm<sup>3</sup> for 3 more consecutive days: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ANC decreases to &lt;1,000/mm<sup>3</sup>: Resume at 5 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If ANC decreases to &lt;1,000/mm<sup>3</sup> during the 5 mcg/kg/day dose, increase dose to 10 mcg/kg/day and follow the above steps</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hematopoietic radiation injury syndrome, acute (Neupogen):</b> SubQ: 10 mcg/kg once daily; begin as soon as possible after suspected or confirmed radiation doses &gt;2 gray (Gy) and continue filgrastim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs or ANC exceeds 10,000/mm<sup>3</sup> after the radiation-induced nadir. ASCO guidelines recommend initiating within 24 hours of exposure of a dose &ge;2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for &ge;7 days (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral blood progenitor cell collection and therapy (Neupogen, Zarxio):</b> SubQ: 10 mcg/kg daily, usually for 6 to 7 days (with apheresis occurring on days 5, 6, and 7). Begin at least 4 days before the first apheresis and continue until the last apheresis; discontinue for WBC &gt;100,000/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe chronic neutropenia (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> Infants &ge;1 month, Children, and Adolescents: SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Congenital:</i> Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; mean dose: 6 mcg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Idiopathic:</i> Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 1.2 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cyclic:</i> Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response;  total daily dose may be administered in 1 or 2 divided doses; mean dose: 2.1 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenia in advanced HIV infection (off-label use):</b> Adolescents &gt;13 years: SubQ: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171208\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881429\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal impairment at treatment initiation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neupogen, Zarxio: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granix:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer&prime;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal toxicity during treatment: Glomerulonephritis due to filgrastim: Consider dose reduction or treatment interruption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881430\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neupogen, Zarxio: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granix: There are no dosage adjustments provided in the manufacturer&prime;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171179\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupogen: filgrastim 300 mcg/mL (1 mL); filgrastim 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupogen: filgrastim 300 mcg/0.5 mL (0.5 mL); filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zarxio: filgrastim-sndz 300 mcg/0.5 mL (0.5 mL); filgrastim-sndz 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Granix: tbo-filgrastim 300 mcg/0.5 mL (0.5 mL); tbo-filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171164\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22627092\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Filgrastim-sndz (Zarxio) is approved as a biosimilar to filgrastim (Neupogen).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46744103\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Prefilled Syringe, Injection [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrofil: 300 mcg/0.5 mL (0.5 mL); 480 mcg/0.8 mL [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171183\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV (Neupogen, Zarxio, Grastofil [Canadian product]): May be administered IV as a short infusion over 15 to 30 minutes (chemotherapy-induced neutropenia) or by continuous infusion (chemotherapy-induced neutropenia) or as an infusion of no longer than 24 hours (bone marrow transplantation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: May be administered SubQ (chemotherapy-induced neutropenia, peripheral blood progenitor cell collection, severe chronic neutropenia, hematopoietic radiation injury syndrome). Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area. Rotate injection site; do not inject into areas that are tender, red, bruised, hardened, or scarred, or sites with stretch marks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Some patients (or caregivers) may be appropriate candidates for subQ self-administration with proper training; patients/caregivers should follow the manufacturer instructions for preparation and administration. Do not skip doses, change schedule, or discontinue without consulting with health care provider. Granix is available in prefilled syringes with and without a needle guard; the prefilled syringe without a safety needle guard is intended for patient/caregiver self-administration. If filgrastim comes in contact with the skin, wash area thoroughly with soap and water; if eye contact occurs, flush exposed eye(s) with water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171182\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelosuppressive chemotherapy recipients with nonmyeloid malignancies:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neupogen (filgrastim), Zarxio (filgrastim-sndz [biosimilar]), Grastofil</b> [Canadian product]<b>:</b> To decrease the incidence of infection (neutropenic fever) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Granix (tbo-filgrastim): </b>To decrease the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of neutropenic fever.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML) following induction or consolidation chemotherapy (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> To reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy in adults with AML.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone marrow transplantation (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> To reduce the duration of neutropenia and neutropenia-related events (eg, neutropenic fever) in patients with nonmyeloid malignancies receiving myeloablative chemotherapy followed by marrow transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic radiation injury syndrome, acute (Neupogen):</b> To increase survival in patients acutely exposed to myelosuppressive doses of radiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral blood progenitor cell collection and therapy (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for apheresis collection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe chronic neutropenia (Neupogen, Zarxio, Grastofil</b> [Canadian product]<b>):</b> Long-term administration to reduce the incidence and duration of neutropenic complications (eg, fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474684\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anemia in myelodysplastic syndrome; Hematopoietic stem cell mobilization for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma  or multiple myeloma; Neutropenia in HIV-infected patients receiving zidovudine (pediatrics); Neutropenia in advanced HIV infection (adolescents and adults); Neutropenia (hepatitis C treatment-associated)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171257\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Filgrastim may be confused with filgrastim-sndz, tbo-filgrastim</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Neupogen may be confused with Epogen, Neulasta, Neumega, Nutramigen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupogen [US, Canada, and multiple international markets] may be confused with Neupro brand name for rotigotine [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Some products available internationally may have vial strength and dosing expressed as units (instead of as micrograms). Refer to prescribing information for specific strength and dosing information.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171171\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (5% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (20%), dizziness (14%), pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (10% to 43%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (5% to 38%), splenomegaly (&ge;5%; severe chronic neutropenia: 30%), petechia (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Ostealgia (5% to 33%; dose and cycle related), back pain (2% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (2% to 15%), cough (14%), dyspnea (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (12% to 48%; dose and cycle related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (&ge;5%), hypertension (&ge;4%), cardiac arrhythmia (&le;3%), myocardial infarction (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (7% to 10%), hypoesthesia (&ge;5%), insomnia (&ge;5%), malaise (&ge;5%), mouth pain (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (&ge;5%), erythema (&ge;2%), maculopapular rash (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (5% to 7%), decreased appetite (&ge;5%), constipation (&ge;2%), diarrhea (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&ge;5%), leukocytosis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Transfusion reaction (2% to 10%), hypersensitivity reaction (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (2% to 3%; no evidence of neutralizing response)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (5% to 9%), limb pain (2% to 7%), muscle spasm (&ge;5%), musculoskeletal pain (&ge;5%) weakness (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (&ge;5%), upper respiratory tract infection (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, capillary leak syndrome, cerebral hemorrhage, decreased bone mineral density, decreased hemoglobin, euthymia nodosum, exacerbation of psoriasis, facial edema, glomerulonephritis, hematuria, hemoptysis, hepatomegaly, hypersensitivity angiitis, hypotension, injection site reaction, osteoporosis, proteinuria, pulmonary alveolar hemorrhage, pulmonary infiltrates, renal insufficiency, respiratory distress syndrome, severe sickle cell crisis, splenic rupture, Sweet syndrome, tachycardia, urticaria, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171186\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim or pegfilgrastim, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Neupogen, Grastofil: Known hypersensitivity to <i>E. coli-</i>derived products</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171168\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse reactions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Serious allergic reactions (including anaphylaxis) have been reported, usually with the initial exposure; may be managed symptomatically with administration of antihistamines, steroids, bronchodilators, and/or epinephrine. Allergic reactions may recur within days after the initial allergy management has been stopped. Do not administer filgrastim products to patients who have experienced serious allergic reaction to filgrastim or pegfilgrastim. Permanently discontinue filgrastim products in patients with serious allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alveolar hemorrhage: Reports of alveolar hemorrhage, manifested as pulmonary infiltrates and hemoptysis (requiring hospitalization), have occurred in healthy donors undergoing PBPC mobilization (off-label for use in healthy donors); hemoptysis resolved upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome: Capillary leak syndrome (CLS), characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration, may occur in patients receiving human granulocyte colony-stimulating factors (G-CSF). CLS episodes may vary in frequency and severity. If CLS develops, monitor closely and manage symptomatically (may require intensive care). CLS may be life-threatening if treatment is delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous vasculitis: Moderate or severe cutaneous vasculitis has been reported, generally occurring in patients with severe chronic neutropenia on chronic therapy. Withhold treatment if cutaneous vasculitis occurs; may be restarted with a dose reduction once symptoms resolve and the ANC has decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: White blood cell counts of &ge;100,000/mm<sup>3</sup> have been reported with filgrastim doses &gt;5 mcg/kg/day. When filgrastim products are used as an adjunct to myelosuppressive chemotherapy, discontinue when absolute neutrophil count (ANC) exceeds 10,000/mm<sup>3</sup> after the ANC nadir has occurred (to avoid potential excessive leukocytosis). Doses that increase the ANC beyond 10,000/mm<sup>3</sup> may not result in additional clinical benefit. Monitor complete blood cell count (CBC) twice weekly during therapy. In patients receiving myelosuppressive chemotherapy, filgrastim discontinuation generally resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, and a return to pretreatment levels in 1 to 7 days. When used for peripheral blood progenitor cell collection, discontinue filgrastim products if leukocytes &gt;100,000/mm<sup>3</sup>. Thrombocytopenia has also been reported with filgrastim products; monitor platelet counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Based on findings of azotemia, hematuria (micro- and macroscopic), proteinuria, and renal biopsy, glomerulonephritis has occurred in patients receiving filgrastim. Glomerulonephritis usually resolved after filgrastim dose reduction or discontinuation. If glomerulonephritis is suspected, evaluate for cause; if likely due to filgrastim, consider dose reduction or treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory distress syndrome: Acute respiratory distress syndrome (ARDS) has been reported. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS; discontinue in patients with ARDS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Splenic rupture: Rare cases of splenic rupture have been reported (may be fatal); in patients with upper abdominal pain, left upper quadrant pain, or shoulder tip pain, withhold treatment and evaluate for enlarged spleen or splenic rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Severe chronic neutropenia: Establish diagnosis of severe chronic neutropenia (SCN) prior to initiation; use prior to appropriate diagnosis of SCN may impair or delay proper evaluation and treatment for neutropenia due to conditions other than SCN. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported to occur in the natural history of congenital neutropenia (without cytokine therapy). Cytogenetic abnormalities and transformation to MDS and AML have been observed with filgrastim when used to manage SCN, although the risk for MDS and AML appears to be in patients with congenital neutropenia. Abnormal cytogenetics and MDS are associated with the development of AML. The effects of continuing filgrastim products in patients who have developed abnormal cytogenetics or MDS are unknown; consider risk versus benefits of continuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disorders: May precipitate severe sickle cell crises, sometimes resulting in fatalities, in patients with sickle cell disorders (sickle cell trait or sickle cell disease); carefully evaluate potential risks and benefits. Discontinue in patients undergoing sickle cell crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytotoxic chemotherapy: Do not use filgrastim products in the period 24 hours before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. Transient increase in neutrophil count is seen 1 to 2 days after filgrastim initiation; however, for sustained neutrophil response, continue until post-nadir ANC reaches 10,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly patients: The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update recommend that prophylactic colony-stimulating factors be used in patients &ge;65 years with diffuse aggressive lymphoma treated with curative chemotherapy (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), especially if patients have comorbid conditions (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients: Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Avoid concurrent radiation therapy with filgrastim products; safety and efficacy have not been established with patients receiving radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging of some dosage forms may contain latex. Granix (tbo-filgrastim), including all components, is not made with natural rubber latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other warnings/precautions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Filgrastim products should not be routinely used in the treatment of established neutropenic fever. CSFs may be considered in cancer patients with febrile neutropenia who are at high risk for infection-associated complications or who have prognostic factors indicative of a poor clinical outcome (eg, prolonged and severe neutropenia, age &gt;65 years, hypotension, pneumonia, sepsis syndrome, presence of invasive fungal infection, uncontrolled primary disease, hospitalization at the time of fever development) (Freifeld 2011; Smith 2006). CSFs should not be routinely used for patients with neutropenia who are afebrile. Dose-dense regimens that require CSFs should only be used within the context of a clinical trial or if supported by convincing evidence (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; International issues: Some products available internationally may have vial strength and dosing expressed as units (instead of as micrograms). Refer to prescribing information for specific strength and dosing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nuclear imaging: Increased bone marrow hematopoietic activity due to colony-stimulating factor use has been associated with transient bone-imaging changes; interpret results accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor growth effects: The G-CSF receptor through which filgrastim products act has been found on tumor cell lines. May potentially act as a growth factor for any tumor type (including myeloid malignancies and myelodysplasia). When used for stem cell mobilization, may release tumor cells from marrow, which could be collected in leukapheresis product; potential effect of tumor cell reinfusion is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299335\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220395\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8446&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belotecan: Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bleomycin: Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171175\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734401\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Filgrastim has been shown to cross the placenta in humans. Information related to the use of granulocyte-colony stimulating factor (G-CSF) in pregnant patients with congenital, cyclic, or idiopathic neutropenia (Boxer 2015; Zeidler 2014) and G-CSF-induced allogeneic peripheral blood stem cells donation is limited (Leitner 2001; Shibata 2003). One review suggests avoiding use during the first trimester until additional outcome information is available (Pessach 2013). Data collected from the Severe Chronic Neutropenia International Registry (SCNIR) note dosing for chronic conditions may need adjusted in pregnant women; the lowest effective dose to maintain the absolute neutrophil count is recommended (Zeidler 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20688322\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">Endogenous G-CSF can be detected in breast milk, however, recombinant G-CSF, when administered orally to infants, was not found to be absorbed (Calhoun 2003). One review suggests waiting until 3 days after the last dose to resume breast-feeding until additional data is available (Pessach 2013).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">The manufacturers recommend that caution be exercised when administering filgrastim products to breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171190\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171177\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chemotherapy-induced neutropenia: Complete blood cell count (CBC) with differential and platelets prior to chemotherapy and twice weekly during growth factor treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bone marrow transplantation: CBC with differential and platelets frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematopoietic radiation injury syndrome (acute): CBC at baseline (do not delay filgrastim for baseline CBC) and approximately every 3 days until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs. Estimate absorbed radiation dose (radiation exposure) based on information from public health authorities, biodosimetry (if available), or clinical findings (eg, onset of vomiting or lymphocyte depletion kinetics).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral progenitor cell collection: Neutrophil counts after 4 days of filgrastim treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe chronic neutropenia: CBC with differential and platelets twice weekly during the first month of therapy and for 2 weeks following dose adjustments; once clinically stable, monthly for 1 year and quarterly thereafter. Monitor bone marrow and karyotype prior to treatment; and monitor marrow and cytogenetics annually throughout treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neutropenia in advanced HIV infection (off-label use): ANC 3 times weekly for 1st week then weekly thereafter (Kuritzkes 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171167\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Filgrastim, filgrastim-sndz, and tbo-filgrastim are granulocyte colony stimulating factors (G-CSF) produced by recombinant DNA technology. G-CSFs stimulate the production, maturation, and activation of neutrophils to increase both their migration and cytotoxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171185\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Filgrastim: 1 to 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tbo-filgrastim: Time to maximum ANC: 3 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Filgrastim: Neutrophil counts generally return to baseline within 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tbo-filgrastim: ANC returned to baseline by 21 days after completion of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 150 mL/kg; Continuous infusion: No evidence of drug accumulation over a 11- to 20-day period</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Systemically degraded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Filgrastim: SubQ: 60% to 70%; Tbo-filgrastim: SubQ: 33%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 4.4 &plusmn; 0.4 hours (Gillan 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Filgrastim: ~3.5 hours; Tbo-filgrastim: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: Filgrastim: 2 to 8 hours; Tbo-filgrastim: 4 to 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171189\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neupogen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/mL (1 mL): $377.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/1.6 mL (1.6 mL): $601.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Granix Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.5 mL (0.5 mL): $359.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/0.8 mL (0.8 mL): $572.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Neupogen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.5 mL (0.5 mL): $400.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/0.8 mL (0.8 mL): $637.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Zarxio Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.5 mL (0.5 mL): $330.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/0.8 mL (0.8 mL): $526.78</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171191\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Accofil (IE);</li>\n      <li>Ambigrast (PH);</li>\n      <li>Biocilin (MX);</li>\n      <li>Biofigran (CO);</li>\n      <li>Biofilgran (MX);</li>\n      <li>Endufil (PH);</li>\n      <li>Filatil (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Filgen (EC, LK, TH);</li>\n      <li>Filgrast (BD);</li>\n      <li>Gran (CN, JP, MY, PH, SG, TH, VN);</li>\n      <li>Granulokine (BR);</li>\n      <li>Grasin (KR);</li>\n      <li>Grastim (BD, LK);</li>\n      <li>Grastofil (IE);</li>\n      <li>Grimatin (JP);</li>\n      <li>Inmunef (MX);</li>\n      <li>Jiexin (CN);</li>\n      <li>Leuco-Plus (TH);</li>\n      <li>Leucogen (ID);</li>\n      <li>Leucostim (JO, KR);</li>\n      <li>Leukokine (ID);</li>\n      <li>Macroleuco (PH);</li>\n      <li>Neograstim (LB);</li>\n      <li>Neufil (BD);</li>\n      <li>Neukine (ID, TH);</li>\n      <li>Neulastim (AE, KW, SA);</li>\n      <li>Neupogen (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Neutromax (PE, PY, VN);</li>\n      <li>Nivestim (AU, GB, HK, IE, MT, MY, TR);</li>\n      <li>Ratiograstim (GB);</li>\n      <li>Recombicyte (PH);</li>\n      <li>Religrast (LK, PH);</li>\n      <li>SciLocyte (PH);</li>\n      <li>Teva Grastim (AU);</li>\n      <li>Tevagastrim (IL);</li>\n      <li>Tevagrastim (HK);</li>\n      <li>White-C (PH);</li>\n      <li>Zarsio (UA);</li>\n      <li>Zarzio (GB, HK, HR, IE, MY, RO, SG, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. <i>Obstet Gynecol</i>. 2015;125(1):197-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/25560125/pubmed\" target=\"_blank\" id=\"25560125\">25560125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calandra G, McCarty J, McGuirk J, et al, &ldquo;AMD3100 Plus G-CSF Can Successfully Mobilize CD34+ Cells From Non-Hodgkin's Lymphoma, Hodgkin's Disease and Multiple Myeloma Patients Previously Failing Mobilization With Chemotherapy and/or Cytokine Treatment: Compassionate Use Data,&rdquo; <i>Bone Marrow Transplant</i>, 2008, 41(4):331-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/17994119/pubmed\" target=\"_blank\" id=\"17994119\">17994119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calhoun DA, Maheshwari A, Christensen RD. Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. <i>Pediatrics</i>. 2003;112(2):421-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/12897302/pubmed\" target=\"_blank\" id=\"12897302\">12897302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19720922\"></a>DiPersio JF, Micallef I, Stiff PJ, et al, &ldquo;Phase III Prospective Randomized Double-Blinded Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin&rsquo;s Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2009a, 27(28):4767-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/19720922/pubmed\" target=\"_blank\" id=\"19720922\">19720922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19363221\"></a>DiPersio JF, Stadtmauer EA, Nadamanee NP, et al, &ldquo;Plerixafor and G-CSF Versus Placebo and G-CSF to Moboilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma,&rdquo; <i>Blood</i>, 2009b, 113(23):5720-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/19363221/pubmed\" target=\"_blank\" id=\"19363221\">19363221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al, &quot;Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2011;52(4):427-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/21205990/pubmed\" target=\"_blank\" id=\"21205990\">21205990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19330875\"></a>Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management and Treatment of Hepatitis C: An Update,&rdquo; <i>Hepatology</i>, 2009, 49(4):1335-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/19330875/pubmed\" target=\"_blank\" id=\"19330875\">19330875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. <i>Blood</i>. 1994;84(5):1427-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/7520770/pubmed\" target=\"_blank\" id=\"7520770\">7520770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granix (tbo-filgrastim) [prescribing information]. North Wales, PA: Teva; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grastofil (filgrastim) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg PL, Sun Z, Miller KB, et al, &ldquo;Treatment of Myelodysplastic Syndrome Patients With Erythropoietin With or Without Granulocyte Colony-Stimulating Factor: Results of a Prospective Randomized Phase 3 Trial by the Eastern Cooperative Oncology Group (E1996),&rdquo; <i>Blood</i>, 2009, 114(12):2393-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/19564636/pubmed\" target=\"_blank\" id=\"19564636\">19564636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstr&ouml;m-Lindberg E, Gulbrandsen N, Lindberg G, et al, &ldquo;A Validated Decision Model for Treating the Anaemia of Myelodysplastic Syndromes With Erythropoietin + Granulocyte Colony-Stimulating Factor: Significant Effects on Quality of Life,&rdquo; <i>Br J Haematol</i>, 2003, 120(6):1037-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/12648074/pubmed\" target=\"_blank\" id=\"12648074\">12648074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated May 1, 2014. Accessed July 30, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf</a>. Updated March 1, 2016. Accessed June 2, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) &ndash; what is the difference? <i>Med Oncol</i>. 1998;15(4):229-233.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/9951685/pubmed\" target=\"_blank\" id=\"9951685\">9951685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson PA, West NJ, Spadoni V, et al, &ldquo;Sterility of Filgrastim (G-CSF) in Syringes,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(11):1238-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/913403/pubmed\" target=\"_blank\" id=\"913403\">913403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    J&auml;dersten M, Montgomery SM, Dybedal I, et al, &ldquo;Long-Term Outcome of Treatment of Anemia in MDS with Erythropoietin and G-CSF,&rdquo; <i>Blood</i>, 2005, 106(3):803-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/15840690/pubmed\" target=\"_blank\" id=\"15840690\">15840690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9456256\"></a>Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection; results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. <i>AIDS</i>. 1998;12(1):65-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/9456256/pubmed\" target=\"_blank\" id=\"9456256\">9456256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuwabara T, Kobayashi S, and Sugiyama Y, &ldquo;Pharmacokinetics and Pharmacodynamics of a Recombinant Human Granulocyte Colony-Stimulating Factor,&rdquo; <i>Drug Metab Rev</i>, 1996, 28(4):625-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/8959393/pubmed\" target=\"_blank\" id=\"8959393\">8959393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leitner G, Loidolt H, Greinix HT, et al. Granulocyte colony-stimulating factor-induced allogeneic peripheral stem cell donation during early pregnancy.<i> Br J Haematol</i>. 2001;115(1):233-234.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/11722442/pubmed\" target=\"_blank\" id=\"11722442\">11722442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23980065\"></a>Malcovati L, Hellstr&ouml;m-Lindberg E, Bowen D, et al, &quot;Diagnosis and Treatment of Primary Myelodysplastic Syndromes in Adults: Recommendations from the European LeukemiaNet,&quot; <i>Blood</i>, 2013, 122(17):2943-64. doi: 10.1182/blood-2013-03-492884.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/23980065/pubmed\" target=\"_blank\" id=\"23980065\">23980065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin WG, Ristow KM, Habermann TM, et al, &ldquo;Bleomycin Pulmonary Toxicity has a Negative Impact on the Outcome of Patients With Hodgkin&rsquo;s Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7614-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/16186594/pubmed\" target=\"_blank\" id=\"16186594\">16186594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCullough JM, Sprentall-Nankervis E, Potcova CA, et al, &ldquo;Recovery and Biological activity of Filgrastim After Injection Through Silicone Rubber Catheters,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(2):186-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/12879546/pubmed\" target=\"_blank\" id=\"12879546\">12879546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neupogen (filgrastim) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozer H, Armitage JO, Bennett CL, et al, &ldquo;2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. American Society of Clinical Oncology Growth Factors Expert Panel,&rdquo; <i>J Clin Oncol</i>, 2000, 18(20):3558-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/11032599/pubmed\" target=\"_blank\" id=\"11032599\">11032599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pessach I, Shimoni A, Nagler A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know? <i>Hum Reprod Update</i>. 2013;19(3):259-267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/23287427/pubmed\" target=\"_blank\" id=\"23287427\">23287427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg PS, Alter BP, Bolyard AA, et al, &ldquo;The Incidence of Leukemia and Mortality From Sepsis in Patients With Severe Congenital Neutropenia Receiving Long-Term G-CSF Therapy,&rdquo; <i>Blood</i>, 2006, 107(12): 4628-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/16497969/pubmed\" target=\"_blank\" id=\"16497969\">16497969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaison G, Eden OB, Henze G, et al, &ldquo;Recommendations on the Use of Colony-Stimulating Factors in Children: Conclusions of a European Panel,&rdquo; <i>E J Pediatr</i>, 1998, 157(12):955-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/9877032/pubmed\" target=\"_blank\" id=\"9877032\">9877032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shibata H, Yamane T, Aoyama Y, et al. Excretion of granulocyte colony-stimulating factor into human breast milk. <i>Acta Haematol</i>. 2003;110(4):200-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/14663166/pubmed\" target=\"_blank\" id=\"14663166\">14663166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh RF, Corelli RL, and Guglielmo BJ, &ldquo;Sterility of Unit Dose Syringes of Filgrastim and Sargramostim,&rdquo; <i>Am J Hosp Pharm</i>, 1994, 51(15):2811-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/7531941/pubmed\" target=\"_blank\" id=\"7531941\">7531941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(28):3199-3212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/26169616/pubmed\" target=\"_blank\" id=\"26169616\">26169616</a>]</span><span class=\"doi\">10.1200/JCO.2015.62.3488</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. <i>J Clin Oncol</i>. 2006;24(19):3187-3205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/16682719/pubmed\" target=\"_blank\" id=\"16682719\">16682719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Younossi ZM, Nader FH, Bai C, et al, &ldquo;A Phase II Dose Finding Study of Darbepoetin Alpha and Filgrastim for the Management of Anaemia and Neutropenia in Chronic Hepatitis C Treatment,&rdquo; <i>J Viral Hepat</i>, 2008, 15(5):370-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/18194172/pubmed\" target=\"_blank\" id=\"18194172\">18194172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zarxio (filgrastim-sndz) [prescribing information]. Princeton, NJ: Sandoz Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeidler C, Grote UA, Nickel A, et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry.<i> Haematologica</i>. 2014;99(8):1395-1402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-drug-information/abstract-text/24997149/pubmed\" target=\"_blank\" id=\"24997149\">24997149</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8446 Version 179.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171203\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171204\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F171247\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F171207\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F171227\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F171208\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15881429\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881430\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171179\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F171164\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22627092\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46744103\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F171183\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F171182\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474684\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171257\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171171\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171186\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171168\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299335\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220395\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171175\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2734401\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20688322\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F171190\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F171177\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171167\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F171185\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171189\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171191\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8446|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-patient-drug-information\" class=\"drug drug_patient\">Filgrastim (including biosimilars of filgrastim): Patient drug information</a></li><li><a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information\" class=\"drug drug_pediatric\">Filgrastim (including biosimilars of filgrastim): Pediatric drug information</a></li></ul></div></div>","javascript":null}